Cargando…
FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
This retrospective review assesses the frequency of surrogate measures used for the first time vs subsequent times in a cancer setting and the surrogate’s strength of correlation with patient-centered outcomes.
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186918/ https://www.ncbi.nlm.nih.gov/pubmed/32338703 http://dx.doi.org/10.1001/jamainternmed.2020.1097 |